Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 6Breast 5Gastrointestinal 4Head & Neck 3Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 265Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 145Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × bintrafusp alfa protein, human × Breast × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT03620201 2024-10-22

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
20 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT04756505 2023-12-27

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT03579472 2022-10-31

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated
38 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03524170 2022-03-07

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡